Enabling the Next Era of Alpha Radioligand Therapies
Meridian is creating the first industrial-scale Pb-212 supply chain—unlocking the full potential of alpha radioligand therapies and driving a new wave of innovation in radiopharmaceuticals.
The Future of Targeted Alpha Therapy
The next breakthrough in precision oncology begins with Pb-212—a powerful alpha-emitting isotope with the potential to revolutionize cancer treatment.
At Meridian Radiopharmaceuticals, we are committed to solving the Pb-212 supply challenge, ensuring biotech and pharmaceutical companies have access to the high-purity isotopes they need to bring life-saving therapies to market.
“Pb-212 represents a transformative step forward in cancer care. By ensuring a reliable, scalable supply, we are unlocking the full potential of alpha-targeted radiopharmaceuticals.”
Scalable. Efficient. Reliable.
Meridian has developed a proprietary, patent-pending manufacturing platform that allows for high-yield production of Pb-212 at a scale previously thought unattainable.
✔ Laboratory-scale validation underway – Expected completion Q2 2025
✔ Key partnership agreements in progress – Enabling commercial-scale deployment within Q2 2025
✔ Non-carrier-added, high-purity Pb-212 – Designed for pharmaceutical-grade applications
We are actively working with industry stakeholders and regulatory bodies to ensure our production aligns seamlessly with commercial needs.
A Next-Generation Alpha-Emitter for Targeted Radiopharmaceuticals
While beta-emitting therapies like Lu-177 have made strides in cancer care, alpha-emitters like Pb-212 offer a new level of precision and potency.
✔ High-energy alpha decay for potent tumor cell destruction
✔ Short half-life (~10.6 hours) enables controlled dosing with reduced radiation exposure
✔ Efficient integration into targeted radiopharmaceuticals using established chelation chemistry
Despite its enormous potential, Pb-212 has remained in short supply—hindering its widespread adoption. We are solving this problem.
Contact us
Lorem ipsum dolor sit amet consectetur odio vel nunc platea orci quis dolor ac aliquet in sit viverra et neque sit sit enim.
Explore our collection of 200+ Premium Webflow Templates
News & articles
Lorem ipsum dolor sit amet consectetur odio vel nunc platea orci quis dolor ac aliquet in sit viverra et neque.
Plans & projects
Lorem ipsum dolor sit amet consectetur odio vel nunc platea orci quis dolor ac aliquet in sit viverra et neque sit sit enim.
Leading the search for tomorro’s cures
Lorem ipsum dolor sit amet consectetur odio vel nunc platea orci quis dolor ac aliquet in sit viverra et neque sit sit enim ornare vestibulum lectus.
Discover our latest research
Lorem ipsum dolor sit amet consectetur odio vel nunc platea orci quis dolor ac aliquet in sit viverra et neque sit sit enim.
We offer an extensive selection of microbiological services
Lorem ipsum dolor sit amet consectetur odio vel nunc platea orci quis dolor ac aliquet in sit viverra et neque sit sit enim.
Supported by our valued partners around the globe
Lorem ipsum dolor sit amet consectetur odio vel nunc platea orci quis dolor ac aliquet in sit viverra et neque sit sit enim ornare vestibulum lectus.
Have any questions?
Lorem ipsum dolor sit amet consectetur odio vel nunc platea orci quis dolor ac aliquet in sit viverra et neque sit sit enim.
What services does Laboratory X provide?
Lorem ipsum dolor sit amet consectetur. Consequat aliquam sit eget sed tortor tempor. Eget varius massa id sit volutpat praesent interdum maecenas eget.
How can I request a quote?
Lorem ipsum dolor sit amet consectetur. Consequat aliquam sit eget sed tortor tempor. Eget varius massa id sit volutpat praesent interdum maecenas eget.
Can I tour Laboratory X facilities?
Lorem ipsum dolor sit amet consectetur. Consequat aliquam sit eget sed tortor tempor. Eget varius massa id sit volutpat praesent interdum maecenas eget.
What certifications does Laboratory X hold?
Lorem ipsum dolor sit amet consectetur. Consequat aliquam sit eget sed tortor tempor. Eget varius massa id sit volutpat praesent interdum maecenas eget.